Shira Eytan, MD, FACE

Panelists discuss discusses how delayed intervention in Stage 2 Type 1 diabetes can accelerate beta cell destruction, leading to more severe clinical onset and increased risk of life-threatening complications like diabetic ketoacidosis.

Panelists discuss how Type 1 diabetes progresses through distinct stages, beginning with asymptomatic autoantibody presence, followed by abnormal blood sugar levels, and ultimately manifesting with classic symptoms like excessive thirst, frequent urination, and unexplained weight loss.

Panelists discuss how early screening for Type 1 diabetes involves testing for autoantibodies in at-risk individuals, particularly those with family history or genetic predisposition, to enable prompt intervention and reduce the risk of diabetic ketoacidosis at diagnosis.

Panelists discuss how managing Type 1 diabetes requires constant vigilance through blood sugar monitoring, insulin administration, and lifestyle adjustments to maintain healthy glucose levels throughout daily life.

Panelists discuss how Type 1 diabetes imposes significant physical, emotional, and financial burdens on patients through the lifelong need for insulin therapy, blood glucose monitoring, lifestyle modifications, and management of potential complications.